Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in... This guideline provides an approach to the prevention of acute antineoplastic‐induced nausea and vomiting (AINV) in children. It was developed by an international, inter‐professional panel using AGREE and CAN‐IMPLEMENT methods. Evidence‐based interventions that provide optimal AINV control in children receiving antineoplastic agents of high, moderate, low, and minimal emetogenicity are recommended. Recommendations are also made regarding selection of antiemetic agents for children who are unable to receive corticosteroids for AINV control, the role of aprepitant and optimal doses of antiemetic agents. Gaps in the evidence used to support the recommendations were identified. The contribution of this guideline to AINV control in children requires prospective evaluation. Pediatr Blood Cancer 2013; 60: 1073–1082. © 2013 Wiley Periodicals, Inc. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pediatric Blood & Cancer Wiley

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Loading next page...
 
/lp/wiley/guideline-for-the-prevention-of-acute-nausea-and-vomiting-due-to-9kR7RYL7cJ

References (423)

Publisher
Wiley
Copyright
Copyright © 2013 Wiley Periodicals, Inc.
ISSN
1545-5009
eISSN
1545-5017
DOI
10.1002/pbc.24508
pmid
23512831
Publisher site
See Article on Publisher Site

Abstract

This guideline provides an approach to the prevention of acute antineoplastic‐induced nausea and vomiting (AINV) in children. It was developed by an international, inter‐professional panel using AGREE and CAN‐IMPLEMENT methods. Evidence‐based interventions that provide optimal AINV control in children receiving antineoplastic agents of high, moderate, low, and minimal emetogenicity are recommended. Recommendations are also made regarding selection of antiemetic agents for children who are unable to receive corticosteroids for AINV control, the role of aprepitant and optimal doses of antiemetic agents. Gaps in the evidence used to support the recommendations were identified. The contribution of this guideline to AINV control in children requires prospective evaluation. Pediatr Blood Cancer 2013; 60: 1073–1082. © 2013 Wiley Periodicals, Inc.

Journal

Pediatric Blood & CancerWiley

Published: Jul 1, 2013

There are no references for this article.